Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) SVP Yakob Liawatidewi sold 1,515 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $21.24, for a total value of $32,178.60. Following the completion of the transaction, the senior vice president now owns 36,670 shares in the company, valued at approximately $778,870.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Yakob Liawatidewi also recently made the following trade(s):

  • On Tuesday, August 13th, Yakob Liawatidewi sold 5,000 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $20.73, for a total value of $103,650.00.

Shares of AMPH traded down $0.33 during trading hours on Monday, hitting $21.29. The company’s stock had a trading volume of 140,555 shares, compared to its average volume of 261,775. The company has a market cap of $1.00 billion, a price-to-earnings ratio of 101.38 and a beta of 1.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The business has a 50 day simple moving average of $21.02 and a two-hundred day simple moving average of $21.17. Amphastar Pharmaceuticals Inc has a 52-week low of $17.71 and a 52-week high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.05. The company had revenue of $79.00 million for the quarter, compared to analysts’ expectations of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. Amphastar Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 EPS. Research analysts predict that Amphastar Pharmaceuticals Inc will post 0.15 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC bought a new stake in Amphastar Pharmaceuticals during the 1st quarter valued at $53,000. Acadian Asset Management LLC purchased a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at about $88,000. Bank of Montreal Can grew its holdings in Amphastar Pharmaceuticals by 130.7% during the 2nd quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock valued at $104,000 after buying an additional 2,789 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in Amphastar Pharmaceuticals by 52,407.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock valued at $150,000 after buying an additional 7,337 shares in the last quarter. Finally, Magnus Financial Group LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at about $204,000. Institutional investors and hedge funds own 47.26% of the company’s stock.

AMPH has been the subject of a number of recent research reports. Wells Fargo & Co set a $29.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Wednesday, July 10th. BidaskClub raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 22nd. Finally, TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $24.64.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Further Reading: What is meant by buying and selling pressure?

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.